SEC Fo	orm 4
--------	-------

Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

••••••••••••••••								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

1. Name and Address of Reporting Person* BOGER JOSHUA S	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC /	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
BOGER JOSHOA 5	MA [VRTX]	X Director 10% Owner					
(Last) (First) (Middle)		X Officer (give title Other (specify below) below)					
C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET	3. Date of Earliest Transaction (Month/Day/Year) 03/16/2004	Chairman & CEO					
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable					
(Street) CAMBRIDGE MA 02139		Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)							

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	03/16/2004		М		7,000	A	\$ <mark>6</mark>	873,577	D	
Common Stock	03/16/2004		S ⁽¹⁾		7,000	D	\$ <mark>9.8</mark>	866,577	D	
Common Stock								217,561	I	10,061 shares 401(k); 207,500 shares in trust ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		I 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Amount of Derivative Securities Security Underlying (Instr. 5) Derivative Security		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option	\$6	03/16/2004		М			7,000	03/08/1995 ⁽³⁾	12/07/2004	Common Stock	7,000	\$0	1,618,223	D	

Explanation of Responses:

1. Transaction made pursuant to Dr. Boger's company approved trading plan established under Rule 10b5-1.

2. Shares held in trust for Dr. Boger's children. Dr. Boger disclaims beneficial ownership of such shares.

3. Right to buy under 1994 Stock and Option Plan, vesting in 20 equal quarterly installments from 3/08/1995.

Remarks:

Kenneth S. Boger, Attorney-In-03/17/2004 Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.